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Introduction: Copperhead envenomation causes local tissue destruction, leading people to seek 
treatment for the pain and swelling. First-line treatment for the pain is opioid medications. There is rising 
concern that an initial opioid prescription from the emergency department (ED) can lead to long-term 
addiction. This analysis sought to determine whether use of Fab antivenom (FabAV) for copperhead 
envenomation affected opioid use.
Methods: We performed a secondary analysis using data from a randomized clinical trial designed 
to determine the effect of FabAV on limb injury recovery following mild to moderate copperhead 
envenomation. Opioid use was a defined secondary outcome in the parent trial. Patients were contacted 
after discharge, and data were obtained regarding medications used for pain and the patients’ functional 
status. This analysis describes the proportion of patients in each treatment group reporting opioid use at 
each time point. It also assesses the interaction between functional status and use of opioids. 
Results: We enrolled 74 patients in the parent trial (45 received FabAV, 29 placebo), of whom 72 were 
included in this secondary analysis. Thirty-five reported use of any opioids after hospital discharge. A 
smaller proportion of patients treated with FabAV reported opioid use: 40.9% vs 60.7% of those in the 
placebo group. The proportion of patients using opioids remained smaller in the FabAV group at each 
follow-up time point. Controlling for confounders and interactions between variables, the model estimated 
that the odds ratio of using opioids after hospital discharge among those who received placebo was 
5.67 times that of those who received FabAV. Patients who reported higher baseline pain, those with 
moderate as opposed to mild envenomation, and females were more likely to report opioid use at follow-
up. Patients with ongoing limitations to functional status had an increased probability of opioid use, 
with a stronger association over time. Opioid use corresponded with the trial’s predefined criteria for full 
recovery, with only two patients reporting opioid use in the 24 hours prior to achieving full limb recovery 
and no patients in either group reporting opioid use after full limb recovery. 
Conclusion: In this study population, the proportion of patients using opioids for pain related to 
envenomation was smaller in the FabAV treatment group at all follow-up time points. [West J Emerg 
Med. 2019;20(3)497–505.]
Duke University, Division of Emergency Medicine, Durham, North Carolina 
Denver Health and Hospital Authority, Rocky Mountain Poison and Drug Center, 
Denver, Colorado
University of Texas Southwestern Medical Center, Department of Emergency 
Medicine, Dallas, Texas
*
†
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Population Health Research Capsule
What do we already know about this issue? 
Expert consensus guidelines call 
for avoidance of nonsteroidal anti-
inflammatory drugs in patients suffering 
from copperhead envenomation. Opioids 
continue to be the recommended 
medication for their pain management.
What was the research question?
Does treatment with Fab antivenom (FabAV) 
in patients who experience a copperhead 
envenomation affect opioid use?
What was the major finding of the study?
The proportion of patients using opioids for 
copperhead envenomation pain was smaller in 
the FabAV group in comparison to placebo.
How does this improve population health?
The risk of iatrogenic addiction when 
prescribing opioids from the emergency 
department remains uncertain. This study 
suggests FabAV treatment decreases likelihood 
of opioid use after a copperhead envenomation.
INTRODUCTION
Between 5000 and 9000 persons in the United States 
(U.S.) seek treatment in an emergency department (ED) for 
snakebite each year.1 There were 2048 calls to U.S. poison 
control centers in 2016 from patients who experienced 
copperhead bites, of whom 1962 sought treatment in 
a healthcare facilty.2 There were close to another 2000 
calls in which the type of snake was not identified.2 
Severe manifestations of crotaline envenomation include 
coagulopathy, hypotension, shock and death; however, these 
are rare complications in copperhead envenomations.3,4,5 
Essentially all copperhead envenomations cause 
local tissue injury, leading to inflammation, necrosis and 
endothelial damage.6,7,8 Edema and pain are the predominant 
symptoms that contribute to the morbidity of disease 
in the weeks following a copperhead envenomation.6,7,8 
Expert consensus guidelines recommend avoiding aspirin 
and nonsteroidal anti-inflammatory drugs (NSAID) due 
to concern for bleeding, platelet dysfunction, and risk 
for prerenal toxicity.9,10 This leaves opioids as the current 
recommended means of pain control for patients suffering a 
copperhead envenomation.9,10 
The current overuse and abuse of opioids has been declared 
an epidemic. The Centers for Disease Control and Prevention 
recently published guidelines to minimize the duration of 
opioid prescriptions.11 Many states have enacted legislation 
to limit prescriptions for opioid medications.12 Emerging 
data suggest that opioid prescriptions from the ED may 
contribute to long-term opioid use and potential abuse.13,14 
Regardless of the cause for pain, increasing the duration of 
the initial opioid prescription decreased the likelihood that 
patients would discontinue opioids.15 Balancing the benefit 
of pain control and the risk of opioids, including potential for 
addiction, is clinically challenging.16 
The primary objective of this secondary analysis was 
to describe post-discharge opioid use in subjects who 
suffered mild to moderate copperhead envenomation and 
were randomized to receive Crotalidae polyvalent immune 
Fab (ovine) antivenom (CroFab®, BTG International Inc., 
West Conshohocken, Pennsylvania) or placebo. A secondary 
objective was to explore the correlation between post-
discharge opioid use and limb function recovery. 
METHODS
Study Design 
This study is a secondary analysis of a multicenter, 
randomized, double-blind, placebo-controlled trial of Fab 
antivenom (FabAV) vs placebo in patients with mild or 
moderate copperhead snake envenomation. The methods 
of this trial, including participant selection, randomization, 
treatment, and the full study protocol have been previously 
published.17 Use of opioid medications was defined as 
a secondary outcome measure during the design of the 
parent study. Patients aged 12 years or older with a mild 
or moderate copperhead envenomation to the distal arm 
or leg presenting within 24 hours of envenomation were 
randomized to receive FabAV or saline placebo. Mild bites 
were defined as swelling that crossed 0-1 major joints (wrist, 
elbow, ankle or knee) and moderate bites were defined as 
swelling that crossed two major joints. The randomization 
was stratified by severity (mild vs moderate), age (adult vs 
adolescent), and extremity affected (upper vs lower). Patients 
were identified and enrolled in the ED. 
Study Protocol 
Patients randomized to FabAV received an initial dose 
of six vials in 250 milliliters (mL) of normal saline solution. 
A repeat dose of six vials of FabAV was administered to 
patients who failed to achieve initial control after the first 
dose. All patients were then administered two vials of 
FabAV at 6, 12, and 18 hours after initial control. Patients 
randomized to receive placebo received normal saline 
solution. Patients were treated by the emergency physician 
on duty upon presentation. Consult with poison control or 
a toxicologist was at the discretion of the treating physician. 
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All other therapies administered to patients, including fluids, 
antiemetics, and pain medications, were at the discretion of 
the treating clinicians. Patients were admitted to the hospital 
or observed in the ED based on local hospital practice. Any 
medications prescribed at discharge were also decided upon by 
the treating clinician. 
Measures
The primary outcome measure for this secondary 
analysis was patient-reported, post-discharge opioid analgesic 
use during the 28 days following envenomation from a 
copperhead snakebite. We defined opioid analgesic use as 
an a priori secondary outcome of the initial study. Patients 
were evaluated on days 3, 7, 10, 14, 17, 21, 24, and 28 
post-envenomation. At each post-envenomation time point, 
patients were asked to report all concomitant medication use. 
This included all analgesic medications used in the 24 hours 
prior to each assessment. They were asked specifically to 
report only on analgesic medications used to treat the pain 
associated with their snakebite. Analgesic use was classified as 
a dichotomous variable: “Opioid use” (including tramadol and 
combination products) and “No opioid use,” which included 
reported use of prescription analgesics (non-opioid), non-
prescription analgesics, and no analgesics.
A secondary outcome for this study was to explore the 
relationship between the main trial’s primary measure of 
limb function recovery, the Patient-Specific Functional Scale 
(PSFS)18, and post-discharge opioid analgesic use. The PSFS 
was administered at all follow-up visits. This measure asked 
patients to report their ability to perform three self-identified 
important activities that they were unable to do or were having 
trouble doing as a result of their snakebite on a scale of 0 
(“unable to perform activity”) to 10 (“able to perform activity 
at the same level as before injury or problem”). We calculated 
the mean score of all three activities, with larger values 
indicating more complete limb function recovery and a mean 
score of 10 indicating full recovery.  
Data Analysis
We conducted all statistical analyses on the modified intent-
to-treat population. Two patients were excluded: one in the 
placebo group was lost to follow-up after discharge and did not 
have any post-discharge assessments completed; and a second 
in the treatment group who had falsified his snakebite was 
discontinued from the study by the treating investigator prior 
to unblinding of treatment arm. The patient with the falsified 
snakebite was included in the analyses for the parent paper, 
and was the only patient in the FabAV treatment group taking 
opioids at the 28-day follow-up. He was excluded from this 
analysis, as our primary goal was to determine whether FabAV 
for the treatment of copperhead snake envenomation affected 
use of opioids. The decision to exclude him from the secondary 
analysis was made prior to the design of the analysis plan. 
We used summary statistics to describe characteristics 
of patients with any post-discharge, opioid analgesic use 
and those with no post-discharge opioid use. Additionally, 
the proportion of patients reporting opioid analgesic use was 
summarized for each follow-up time point, separated by 
treatment group. The differences between treatment groups are 
presented with exact 95% confidence intervals and p-values 
from a two-tailed Wald equivalence test. 
To study the relationship between opioid use, functional 
status, and treatment with FabAV, we modeled the mean 
probability of opioid use across all visits using generalized 
estimating equations (GEE). A first-order autoregressive 
covariance structure was chosen to model the within-subject 
variance from visit to visit. The GEE model included effects 
for treatment group, visit number, PSFS score, envenomation 
severity (mild vs moderate), envenomation location (upper 
vs lower extremity), sex, age category (adolescent vs adult), 
time to treatment, and the interactions between treatment 
group and PSFS score, treatment group and visit number, and 
visit number and PSFS. We performed a backward stepwise 
regression and sequentially removed non-significant effects 
(defined as p>0.10 for interaction terms and p>0.05 for main 
effects). Once the model was finalized, each excluded term 
was added back separately to ensure that it did not drastically 
affect the results of the model, ensuring that there were no 
interactions unaccounted for in the final model. Results are 
presented as the mean probability of opioid use across all 
visits and the odds ratio of opioid use among patients treated 
with FabAV compared to those treated with placebo. 
Missing values for opioid use and PSFS scores were 
imputed using the last observation carried forward method. 
RESULTS
Demographics and clinical characteristics 
We included 72 patients in this secondary analysis. Thirty-
five (48.6%) patients reported use of an opioid at least once at 
a post-discharge, follow-up time point. A greater proportion 
of patients in the placebo group, those with moderate severity 
envenomation, females, and those patients with higher 
baseline pain scores reported post-discharge opioid analgesic 
use (Table 1). Rates of opioid use were similar between 
patients who suffered an upper extremity envenomation 
when compared to those who suffered a lower extremity 
envenomation. 
Primary outcome 
A greater proportion of patients treated with placebo 
reported opioid analgesic use at each follow-up time point 
compared to those treated with FabAV (Figure 1). All patients 
who experienced a copperhead snake envenomation and were 
treated with FabAV discontinued opioids by 21 days post-
envenomation. There were patients within the placebo group 
who reported opioid use at each time point assessed (Table 
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Any post-discharge opioid use
N=35
No post-discharge opioid use
N=37
Total 
N=72
Treatment, N (%)
FabAV 18 (40.9%) 26 (59.1%) 44
Placebo 17 (60.7%) 11 (39.3%) 28
Age in years: mean (SD) 41.3 (15.95) 45.3 (19.28) 43.3 (17.73)
Age category, N (%)
Adolescent 4 (50.0%) 4 (50.0%) 8
Adult 31 (48.4%) 33 (51.6%) 64
Baseline pain score*: mean (SD) 6.8 (2.57) 4.9 (2.83) 5.8 (2.85)
Envenomation location, N (%)
Lower extremity 22 (48.9%) 23 (51.1%) 45
Upper extremity 13 (48.1%) 14 (51.9%) 27
Envenomation severity, N (%)
Mild 29 (45.3%) 35 (54.7%) 64
Moderate 6 (75.0%) 2 (25.0%) 8
Gender, N (%)
Female 19 (54.3%) 16 (45.7%) 35
Male 16 (43.2%) 21 (56.8%) 37
Hours to treatment mean (SD) 6.8 (5.06) 7.4 (5.53) 7.1 (5.28)
Table 1. Demographic and clinical characteristics of subjects with mild or moderate copperhead envenomation, reported by use of post-
discharge opioid analgesics.
2). Data from the main outcomes publication shows that there 
was opioid use in the FabAV group at day 28.17 This represented 
one patient, who was one of the two patients excluded from 
this secondary analysis. This patient was found to have falsified 
a snakebite; thus, opioids taken would not have been used for 
treatment of pain associated with envenomation. 
Secondary outcomes 
The final GEE model included the effects for treatment, 
visit number, PSFS score, the interaction between treatment and 
visit number, and the interaction between visit number and PSFS 
score. The model estimated mean probability of subjects using 
an opioid, after adjusting for time, PSFS, and the interaction 
between the two, was lower for the FabAV treatment group than 
the placebo group (Table 3). Overall, adjusting for other factors, 
patients in the placebo group were 5.67 times as likely to use an 
opioid post-discharge compared to patients in the FabAV group 
(p=0.008; Table 3). 
In the GEE model, multiple variables were found to 
influence each other. The interaction between treatment and 
visit number was significant, indicating the effect of treatment 
on opioid use was dependent on time (p=0.028; Table 4). The 
estimated odds of opioid use was higher in the group treated with 
placebo at each time point, with increasing odds as time passed. 
At three days post-envenomation, the estimated odds of using 
opioids among the group treated with placebo was 1.38 times 
that of the FabAV group (95% CI 0.58, 3.27); by 14 days post-
envenomation, the odds were 4.63 times for the placebo group 
in comparison to FabAV (95% CI 1.47, 14.62). The interaction 
between visit number and PSFS score was significant (p=0.042; 
Table 4). Patients with poor functional recovery, demonstrated 
by lower PSFS scores, were more likely to use opioids; this 
association also appeared stronger over time. At three days post-
envenomation, PSFS score of one point lower was associated 
with a 1.08 times greater odds of opioid use (95% CI 0.97, 1.20). 
At 14 days post-envenomation, the odds were 1.29 times greater 
(95% CI 1.14, 1.47) and at 28 days post-envenomation the odds 
increased to 1.65 (95% CI 1.26, 2.17). 
Finally, only two patients (both in the FabAV group) reported 
using opioids in the 24 hours prior to achieving full limb function 
recovery on the PSFS, and no subjects in either treatment group 
reported using opioids after reaching full recovery. 
Missing Values 
Overall, only 3.5% of missing opioid use values were 
imputed. Within the placebo group, three patients had a total of 
eight imputed values; for the treatment group, six patients had a 
total of 12 imputed values.
*Pain scores were evaluated using the 11-point numerical rating scale, with values ranging from 0 (no pain) -10 (worst pain ever).
FabAV, Fab antivenom; SD, standard deviation.
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DISCUSSION
Although antivenom administration is the standard of care for 
rattlesnake envenomation, its use in copperhead envenomation has 
been controversial.9,10,17,19-21 This debate has been influenced by 
the low mortality associated with these bites, questionable effects 
on coagulation, the high cost of the drug, and the prior uncertainty 
about the efficacy for recovery from tissue injury.20, 22-24 There is 
also concern about allergic reaction to antivenom, although this 
is a rare occurrence since the ovine preparation used in FabAV 
was developed.25,26 A recent study did find that patients had earlier 
return of limb function following mild to moderate copperhead 
envenomation after treatment with FabAV.17 This same study 
found that subjects who were treated with FabAV also had lower 
pain scores and less opioid use than those subjects who were 
treated with placebo.17 The main argument against antivenom that 
now remains is one of cost vs benefit.27,28
It is often hard to predict how long patients will require pain 
control when they are seen at the time of initial injury. In general, 
patients with mild to moderate envenomation due to a copperhead 
bite have ongoing pain and swelling on average for about two 
weeks, although some have symptoms for prolonged periods of 
time.6,7,17,29 This secondary analysis found that less than half of 
all patients who suffered a copperhead envenomation required 
any use of opioids as an outpatient. Of note, those patients who 
were treated with FabAV had a decreased likelihood of opioid 
use and ceased use of opioids sooner than those subjects who 
received placebo. 
There is no consensus in the literature about what initial 
duration or amount of opioid leads to addiction. In the opioid-
naïve patient, it has been found that opioid prescriptions from the 
ED are associated with a lower risk of progression to long-term 
use than those prescribed in other settings.30 However, emerging 
data suggest that receipt of initial opioid prescriptions from the 
ED can contribute to long-term opioid abuse and addiction.14,15 
There is a sharp increase in the probability of ongoing opioid use 
at one year when the initial prescription is for a duration of more 
than five days (hazard ratio for discontinued use one year after a 
3-4 day supply 0.70; hazard ratio for discontinued use one year 
after a 5-7 day supply 0.48).15 This suggests that the risks of side 
effects from opioids and potential for long-term addiction should 
play a role in the decision-making process when considering 
treatment with antivenom following a copperhead envenomation. 
The risk and resultant cost of treatment for long-term addiction 
must also factor into any cost benefit analyses when discussing 
treatment with FabAV. 
No current literature defines the number of patients who 
develop opioid use disorder after suffering a copperhead 
envenomation. Male gender and a younger age are both risk 
factors for the development of opioid use disorder.32 These same 
patient characteristics are associated with increased risk 
of unintentional snake envenomation.33,34 Although males 
are at higher risk for opioid use disorder, the rate at which 
females overdose on prescription opioids is much higher.35 
In this study, we found that females were more likely to use 
opioids after a snake envenomation. While we do not know 
what the rate of opioid overdose might be in this specific 
Figure 1. Proportion of subjects with mild or moderate copperhead envenomation who reported using opioid analgesics in the 
previous 24 hours. 
FabAV, Fab antivenom.
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Days from envenomation Treatment Opioid use (%)
Difference between treatment 
groups (95% CI) P-value
3 Fab AV 34.1% -8.8% (-31.8%, 14.3%) 0.456
Placebo 42.9%
7 Fab AV 27.3% -12.0% (-34.4%, 10.4%) .0293
Placebo 39.3%
10 Fab AV 11.4% -17.2% (-36.4%, 2.0%) 0.079
Placebo 28.6%
14 Fab AV 4.5% -20.5% (-37.6%, -3.3%) 0.020
Placebo 25.0%
17 Fab AV 4.5% -20.5% (-37.6%, -3.3%) 0.020
Placebo 25.0%
21 Fab AV 0.0% -14.3% (-27.2%, -1.3%) 0.031
Placebo 14.3%
24 Fab AV 0.0% -10.7% (-22.2%, 0.7%) 0.067
Placebo 10.7%
28 Fab AV 0.0% -7.1% (-16.7%, 2.4%) 0.067
Placebo 7.1%
Table 2. Proportion of subjects with mild or moderate copperhead envenomation who reported using opioid analgesics in the previous 
24 hours by time post-envenomation and treatment group.
FabAV, Fab antivenom; CI, confidence interval. 
patient population, any treatment that decreases the need for 
opioids, and therefore the risk for opioid dependence and 
addiction, should be considered. 
There is another sharp increase in the probability of 
opioid use at one year when the initial prescription went 
beyond 30 days.15 Receiving a refill opioid prescription was 
also associated with an increased risk of ongoing opioid 
use at one year.15 In this secondary analysis, all copperhead 
snake envenomation subjects in the FabAV treatment 
arm had discontinued opioids by day 21, while 7% of the 
patients in the placebo group reported ongoing opioid use 
at 28 days post-envenomation. We did not follow patients 
beyond 28 days post-envenomation, but this raises concerns 
that the patients in the placebo group who continued to use 
opioids were at risk for development of opioid use disorder. 
The parent study used the PSFS to report limb function 
disability following envenomation. This scale was initially 
designed to measure functional changes in patients with 
musculoskeletal disorders.18 It has since been validated 
in snakebite-envenomation patient populations.7,29,31 In 
this secondary analysis, we find that cessation of opioids 
correlates to an improvement in the PSFS. This further 
validates use of PSFS as a marker for patient recovery. It is 
especially concerning that the risk of opioid use with lack 
of improved PSFS scores, indicating ongoing disability, 
increased with time. 
LIMITATIONS
This study is a secondary analysis of data that were collected 
prospectively in a blinded fashion during the parent clinical trial. 
Use of opioid analgesics was defined as a secondary outcome 
measure a priori; this analysis was planned prior to any data 
review. However, the results should be treated as exploratory due 
to the design limitation. Future studies should focus on opioid use 
as a primary outcome and ultimately the impact of antivenom on 
opioid dependence consequent to snake envenomation. The latter 
will require large numbers and pragmatic designs.
These analyses relied on patient self-reported use of 
analgesics. We did not collect data on the doses that patients were 
taking or whether the medication was from an initial prescription 
or if they required a second prescription due to ongoing pain. 
Further study would be needed to determine whether non-opioid 
medications or non-pharmacologic means of pain treatment are as 
effective as opioids and whether they can be safely used to treat 
pain associated with copperhead envenomations. 
The parent study did not limit use of concomitant treatments 
in the ED, such as pain medications, fluids or antiemetics. It 
is possible that use of these may influence patient experience 
of acute pain and need for ongoing treatment for pain after 
discharge. Additionally, opioid prescriptions were given at the 
discretion of the blinded treating physician and not determined 
by the study protocol. Simply receiving a prescription for opioids 
may influence whether patients take these medications. 
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Michael Mullins, MD2
Spencer Greene, MD3
Eric Toschlog, MD4
Eugenia Quackenbush, MD5
S. Rutherford Rose, PharmD6
Richard Schwartz, MD7
Nathan Charlton, MD8
Brandon Lewis, DO9
Nicklaus Brandehoff, MD10
Treatment 
group
Mean (standard 
error) probability 
of opioid use Odds ratio p-value
FabAV 0.036 (0.019) 0.008
Placebo 0.175 (0.047) 5.67 (1.57, 20.45)
Table 3. Model estimated marginal mean probability of opioid 
analgesic use in subjects with mild or moderate copperhead 
envenomation.
FabAV, Fab antivenom.
Effect Chi-square p-value
Treatment 1.83 0.177
Time (visit number) 0.14 0.707
PSFS score 1.77 0.183
Time *treatment interaction 4.84 0.028
Time *PSFS interaction 4.15 0.042
Table 4. Results of generalized estimating equations model 
of probability of opioid use in subjects with mild or moderate 
copperhead envenomation by fixed effect.
PSFS, Patient-specific functional scale. 
This study only enrolled patients with a mild or moderate 
copperhead envenomation. As these envenomations tend to be 
less severe than those of other Crotalinae snakes, it is unclear 
whether opioid use would differ based on FabAV treatment for 
envenomations of other snake species. It is also unclear 
whether the more common systemic effects in other snake 
envenomations may affect the use and duration of opioid 
treatments. We were unable to perform subanalyses to 
determine whether the degree of envenomation (mild vs 
moderate) affected opioid use due to the low number of 
patients in the subgroups. This would be important to study if 
future studies enroll a larger number of patients. 
CONCLUSION
In a randomized, double-blind, placebo-controlled trial 
of Fab antivenom vs placebo, patients who received FabAV 
had a decreased likelihood of opioid use. Lower numbers 
on the Patient-Specific Functional Scale, indicating ongoing 
disability when compared to baseline, correlated with a greater 
probability of opioid use.
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